A surprise loss of 23,000 jobs in July and weaker past hiring have put the labour market under fresh scrutiny. Slower growth can shift expectations for interest rates, which often steers money toward sectors seen as more resilient. Healthcare stocks sit firmly in that conversation. This article walks through three larger healthcare companies from our screener that appear well positioned or vulnerable to these cross currents, so you can decide how they might fit your watchlist.

The stocks in the list below are just a starting sample, and the full screen surfaced 38 more healthcare companies with similarly detailed narratives that are not covered here. If you want to go deeper on this idea right now, head straight to the Healthcare Stocks screener to identify, compare, and analyze the potential higher conviction opportunities that best fit your own criteria.

Axsome Therapeutics (AXSM)

Axsome Therapeutics is a biopharma company focused on treatments for central nervous system disorders, with approved drugs for depression, narcolepsy related sleepiness, and migraine. It generated about US$708 million from its CNS therapies, and the company is almost entirely US focused based on reported revenue. Axsome Therapeutics currently has a market cap of roughly US$10.8b.

Axsome Therapeutics operates at the intersection of mental health, sleep disorders, and migraine, with a roster of approved drugs and late stage trials that could broaden its CNS footprint further. Analysts have published detailed cash flow estimates that imply considerable value in the stock, yet Axsome Therapeutics is still loss making and relies heavily on a small group of products, while carrying higher risk borrowings and facing intense competition. With new regulatory milestones on the horizon and a cooling jobs market that can push more investors toward healthcare, Axsome Therapeutics is the kind of stock that may warrant closer examination of the trade off between its growth ambitions and the financial and execution risks behind them.

Axsome Therapeutics sits at the crossroads of big CNS ambitions and a concentrated product lineup. Before you decide how that trade off fits your watchlist, read the analysis report for Axsome Therapeutics

Build your own CNS and healthcare shortlist

Axsome Therapeutics and the two other healthcare stocks in this article all came from a single screen, but the real value is in tailoring your own filters. Use our flexible Screener to mix valuation, growth, and quality metrics, or start with one of our curated Investing Ideas.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals develops RNA interference medicines that target the genetic drivers of diseases such as amyloidosis, hypercholesterolemia, hemophilia, and several metabolic and neurology conditions. It generates about US$4.8b from discovering, developing, manufacturing, and commercializing these RNAi therapeutics across its portfolio, and the company currently has a market cap of roughly US$29.3b.

Alnylam Pharmaceuticals sits at the center of a fast evolving RNA medicine field, with AMVUTTRA and other RNAi therapies already contributing to profitability and a late stage pipeline in cardiomyopathy, hypertension, and neurological disease. Analysts cite long term earnings potential and recent revenue guidance that reflects ongoing product demand. At the same time, the stock carries concentration risk in the TTR franchise, high investment needs, and a P/E above many biotech peers. In a cooling jobs market that can push more investors toward healthcare, this mix of quality-focused growth, debt supported returns, and recent analyst target cuts suggests Alnylam Pharmaceuticals may warrant closer review before deciding whether it belongs on your watchlist.

Alnylam Pharmaceuticals is where high-conviction RNA medicine meets a valuation many investors still question. Get the full story in the analyst forecasts for Alnylam Pharmaceuticals and see what the current P/E might be missing.

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals is a commercial stage biotech focused on RNA targeted medicines across rare diseases and neurology, with approved treatments for conditions such as spinal muscular atrophy, hereditary angioedema, familial chylomicronemia syndrome, and ALS. The company reports about US$874 million in revenue from Ionis Operations and currently has a market cap of roughly US$9.4b.

Ionis Pharmaceuticals sits at an interesting crossroads for healthcare investors. The company has a growing portfolio of commercial rare disease drugs, fresh approvals like TRYNGOLZA, and a long list of late stage RNA programs that analysts link to potential earnings growth, all supported by partnerships with Biogen, AstraZeneca, Novartis, Roche, and others. On the other side, the stock is still loss making, relies on external borrowing, and key programs such as eplontersen have faced setbacks that led to analyst model changes. Investors who are looking for exposure to RNA medicines with meaningful upside potential but are comfortable with clinical and pricing risk may find Ionis Pharmaceuticals worth a closer look.

Ionis Pharmaceuticals sits at the point where RNA partnerships and late stage programs could reshape future earnings profiles. Before this story moves further, review the analyst forecasts for Ionis Pharmaceuticals and see what current expectations might be missing.

Seeking Fresh Alternatives Beyond Healthcare?

Fresh stock ideas move fast. Some are building quiet breakout momentum while others stay under the radar for now. Do your homework before the crowd catches up and consider researching opportunities early.

• Spot companies building real traction in digital assets before headlines catch up by scanning the curated 20 cryptocurrency and blockchain stocks and see which stocks still look early in their story.
• Track cash-generating miners while gold sentiment keeps swinging and use the focused 30 elite gold producer stocks to narrow in on producers with stronger fundamentals and discipline.
• Follow the shift toward smarter factories and logistics and use the hand picked 36 robotics and automation stocks to zero in on automation stocks driving that change right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.